

## Special Issue

# Multitarget Drug Discovery and Pharmacology

### Message from the Guest Editor

The lack of efficiency of traditional drug therapies has stimulated pharmacological research for searching alternative approaches; as a result, the multi-target-directed ligands approach (MTDL) recently emerged with the aim of overcoming these limitations; in this approach, small molecules are capable of simultaneously modulating several relevant therapeutic targets of a certain disease. Interest in MTDLs is experiencing a continuous increase, supported by the number of scientific publications on this topic, together with the fact that numerous drugs with a multitarget mode of action have already been approved by FDA. The aim of this Special Issue is to provide an overview of recent pharmacological research of MTDL's against multifactorial diseases; topics will include but are not limited to cancer, Alzheimer's, Parkinson, diabetes, and infectious diseases.

---

### Guest Editor

Dr. Óscar López

Department of Organic Chemistry, University of Seville, Sevilla, Spain

---

### Deadline for manuscript submissions

closed (15 April 2022)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/si/57228](https://mdpi.com/si/57228)

*Pharmaceuticals*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 6.1  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)